Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sunitinib + docetaxel in large operable or locally advanced breast cancer
2007-007257-31Phase 2Terminated
- Sponsor
- IPOLFG
- Start
- Jan 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib and docetaxel in breast cancer, sponsored by IPOLFG. Primary endpoint: Complete response rate at surgery. Started Jan 2008; status: terminated.
02
Drugs
sunitinibdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-007257-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007257-31.